KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBT (2016 - 2025)

Exact Sciences (EXAS) has disclosed EBT for 16 consecutive years, with -$85.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 90.29% to -$85.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$203.9 million, a 80.32% increase, with the full-year FY2025 number at -$203.9 million, up 80.32% from a year prior.
  • EBT was -$85.1 million for Q4 2025 at Exact Sciences, down from -$17.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.0 million in Q3 2023 to a low of -$876.0 million in Q4 2024.
  • A 5-year average of -$145.8 million and a median of -$104.7 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: soared 100.69% in 2023, then plummeted 3688.49% in 2024.
  • Exact Sciences' EBT stood at -$224.9 million in 2021, then soared by 42.22% to -$129.9 million in 2022, then surged by 61.23% to -$50.4 million in 2023, then plummeted by 1638.86% to -$876.0 million in 2024, then skyrocketed by 90.29% to -$85.1 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's EBT are -$85.1 million (Q4 2025), -$17.8 million (Q3 2025), and -$57000.0 (Q2 2025).